Aardvark Therapeutics reported asset growth of -44.76% for the quarter ended Jun 2026. These growth metrics cover 9 quarters of results from Jun 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Growth MetricsGrowth | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|
| Growth Ratios | |||||||||
| Assets Growth (1y) | 51.19% | -37.21% | -44.76% | ||||||
| Assets (QoQ) | 102.59% | -6.08% | -9.66% | -12.05% | -15.87% | -17.37% | |||
| Capital Expenditures Growth (1y)Capex Growth (1y) | -2.15% | -20.00% | |||||||
| Capital Expenditures (QoQ)Capex (QoQ) | 1,760.00% | -94.62% | 20.00% | -95.60% | |||||
| Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) | -23.67% | 135.57% | 184.06% | ||||||
| Cash & Equivalents (QoQ)Cash & Equiv. (QoQ) | -57.00% | -1.91% | 51.11% | 19.77% | 32.70% | 18.28% | |||
| Cash from Investing Activities Growth (1y)Cash from Investing Growth (1y) | -2,252,380.00% | 10,217.20% | 585,020.00% | 304.30% | 130.41% | 205.56% | |||
| Cash from Investing Activities (QoQ)Cash from Investing (QoQ) | -1,760.00% | 94.62% | -237,800.00% | -846.82% | 108.35% | 210.83% | -16.90% | 40.93% | -16.06% |
| Cash from Operations Growth (1y)Cash from Ops. Growth (1y) | -420.00% | -133.55% | -307.84% | -117.55% | -65.69% | -78.78% | |||
| Cash from Operations (QoQ)Cash from Ops. (QoQ) | -92.47% | 6.17% | -95.37% | -47.38% | 13.56% | -63.86% | -4.22% | -12.25% | 6.73% |
| EBIT Growth (1y) | -382.27% | -160.96% | -247.73% | -97.93% | -114.56% | 4.82% | |||
| EBIT (QoQ) | -179.73% | 16.17% | -85.62% | -10.79% | -51.37% | -11.70% | -5.65% | -20.10% | 32.85% |
| EBT Growth (1y) | -349.47% | -162.09% | -299.71% | -101.29% | -132.11% | -0.20% | |||
| EBT (QoQ) | -164.94% | 25.33% | -113.47% | -6.44% | -54.49% | -13.87% | -7.50% | -22.73% | 33.31% |
| EPS (Basic) Growth (1y) | -28.53% | 51.77% | 28.36% | 59.18% | -40.25% | 0.58% | |||
| EPS (Basic) (QoQ) | -150.14% | 23.62% | -109.43% | 67.88% | 6.12% | -13.44% | -19.34% | -10.35% | 33.45% |
| EPS (Diluted) Growth (1y) | -28.53% | 51.77% | 28.36% | 59.18% | -40.25% | 0.58% | |||
| EPS (Diluted) (QoQ) | -150.14% | 23.62% | -109.43% | 67.88% | 6.12% | -13.44% | -19.34% | -10.35% | 33.45% |
| Free Cash Flow Growth (1y)FCF Growth (1y) | -418.82% | -130.62% | -307.42% | -117.38% | -65.69% | -77.14% | |||
| Free Cash Flow (QoQ)FCF (QoQ) | -96.26% | 8.08% | -95.28% | -47.26% | 12.76% | -62.40% | -4.19% | -12.25% | 6.73% |
| Net Cash Flow Growth (1y)NCF Growth (1y) | -1,500.77% | -100.64% | 441.04% | 137.63% | 143.79% | 2,355.53% | |||
| Net Cash Flow (QoQ)NCF (QoQ) | 3,682.37% | -104.95% | -429.67% | -70.27% | 98.56% | 2,725.89% | -41.55% | 98.11% | -25.82% |
| Net Income Growth (1y) | -327.46% | -163.66% | -290.15% | -100.46% | -131.88% | -0.14% | |||
| Net Income (QoQ) | -150.18% | 23.25% | -109.92% | -6.05% | -54.32% | -13.57% | -7.86% | -22.67% | 33.36% |
| Net Income towards Common Stockholders Growth (1y)Net Income Growth (1y) | -327.46% | -163.66% | -290.15% | -100.46% | -131.88% | -0.14% | |||
| Net Income towards Common Stockholders (QoQ)Net Income (QoQ) | -150.18% | 23.25% | -109.92% | -6.05% | -54.32% | -13.57% | -7.86% | -22.67% | 33.36% |
| Operating Income Growth (1y)Op. Inc Growth (1y) | -382.27% | -160.96% | -247.73% | -97.93% | -114.56% | 4.82% | |||
| Operating Income (QoQ)Op. Inc (QoQ) | -179.73% | 16.17% | -85.62% | -10.79% | -51.37% | -11.70% | -5.65% | -20.10% | 32.85% |
| Profit After Tax Growth (1y)PAT Growth (1y) | -349.47% | -162.09% | -299.71% | -101.29% | -132.11% | -0.20% | |||
| Profit After Tax (QoQ)PAT (QoQ) | -164.94% | 25.33% | -113.47% | -6.44% | -54.49% | -13.87% | -7.50% | -22.73% | 33.31% |
| Return on Assets [ROA] Growth (1y)ROA Growth (1y) | 0.00M | -0.01M | |||||||
| Return on Assets [ROA] (QoQ)ROA (QoQ) | -43.00 | 0.00M | 0.00M | 0.00M | 0.00M | ||||
| Return on Capital Employed [ROCE] Growth (1y)ROCE Growth (1y) | 0.00M | -0.01M | |||||||
| Return on Capital Employed [ROCE] (QoQ)ROCE (QoQ) | -86.00 | 0.00M | 0.00M | 0.00M | 0.00M | ||||
| Return on Equity [ROE] Growth (1y)ROE Growth (1y) | 0.00M | -0.01M | |||||||
| Return on Equity [ROE] (QoQ)ROE (QoQ) | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | ||||
| Share-based Compensation Growth (1y)Stock Comp. Growth (1y) | 247.76% | 1,096.23% | 941.67% | 813.87% | 760.09% | 207.57% | |||
| Share-based Compensation (QoQ)Stock Comp. (QoQ) | -20.90% | 171.70% | 20.14% | 34.68% | 172.10% | 136.59% | 5.40% | 26.76% | -2.69% |
Pull Aardvark Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=AARD&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "AARD", "statement": "Growth", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=AARD&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();